Heron Therapeutics, Inc. (HRTX) NASDAQ
0.45
-0.3772(-45.60%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.45
-0.3772(-45.60%)
Currency In USD
| Previous Close | 0.83 |
| Open | 0.68 |
| Day High | 0.69 |
| Day Low | 0.45 |
| 52-Week High | 2.3 |
| 52-Week Low | 0.45 |
| Volume | 21.89M |
| Average Volume | 2.13M |
| Market Cap | 71.07M |
| PE | -2.5 |
| EPS | -0.18 |
| Moving Average 50 Days | 0.95 |
| Moving Average 200 Days | 1.17 |
| Change | -0.38 |
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
GlobeNewswire Inc.
Feb 17, 2026 1:30 PM GMT
CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, F
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
GlobeNewswire Inc.
Jan 09, 2026 2:29 PM GMT
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We ar
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
GlobeNewswire Inc.
Dec 04, 2025 1:15 PM GMT
APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitantAprepitant alone, or adde